Locations
Company type
Result types
Industries
Employees
Founding year
The B2B platform for the best purchasing descision. Identify and compare relevant B2B manufacturers, suppliers and retailers
Close
Filter
Result configuration
Continents
Select continent
Locations
Result types
Company type
Select company type
Industries
Select industry
Company status
Select company status preset
Number of employees
Min.
Max.
Founding year
Harbour Biomed
Huangpu District, China
D
51-100 Employees
2016
Key takeaway
Harbour BioMed is dedicated to the development of novel antibody therapeutics, including bispecific antibodies that leverage their HCAb platform to create immune cell engagers capable of more effective tumor targeting. Their innovative approach aims to enhance treatment potency and safety, particularly in immunology and oncology.
Reference
Product
Bispecific Antibodies-hbm holdings
Biointron Biological Inc.
Taizhou, China
D
251-500 Employees
2012
Key takeaway
Biointron specializes in bispecific antibody production, highlighting its expertise in recombinant antibody discovery and development. With a commitment to advancing biotechnology and improving human health, Biointron has successfully delivered numerous recombinant antibodies to a diverse range of biotech and pharmaceutical companies worldwide.
Reference
Core business
Biointron-Antibody Discovery | Antibody Production | Stable cell line | Protein Expression | CRO
WuXi Biologics
Xuancheng, China
D
5001-10000 Employees
2014
Key takeaway
WuXi XDC, a subsidiary of WuXi Biologics, specializes in the development and manufacturing of bispecific antibodies, offering a comprehensive platform that integrates bioconjugation services. Their expertise includes advanced technologies for the generation and optimization of novel antibody therapeutics, ensuring high-quality standards that meet global regulatory requirements.
Reference
Product
Services & Solutions – Technologies – Antibody Generation & Engineering
WuXi Biologics offers a full spectrum of discovery services for the generation, characterization, engineering, optimization and selection of high-potency, novel, preclinical candidate (PCC) antibody therapeutics (e.g., monoclonal, bispecific and multispecific antibodies). Our discovery technology platforms include the WuXiBody® Bispecific Antibody Platform, WuXiHybridTM hybridoma systems, WuXiLiAb® phage display and VHH naive and immune libraries and the OmniAb® and Alloy Therapeutic transgenic technologies.
Looking for more accurate results?
Find the right companies for free by entering your custom query!
25M+ companies
250M+ products
Free to use
Biocytogen
Daxing District, China
D
1001-5000 Employees
2008
Key takeaway
Biocytogen specializes in next-generation antibody drug development, offering a platform that facilitates the discovery and development of bispecific antibodies. Their innovative technologies and genetically modified models enhance the research capabilities for creating advanced antibody therapies.
Reference
Core business
Antibody Discovery, Models & Preclinical Testing | Biocytogen
Biocytogen partners with researchers to provide high-quality gene-editing services, animal models, preclinical efficacy testing and antibody discovery services.
KYinno
Dongcheng District, China
D
11-50 Employees
2017
Key takeaway
The company has developed a Common Light Chain mouse named KY-CLC-mouse, which addresses the central issue of light chain matching in bispecific antibody (BsAb) manufacturing. Their specialized services, including custom-designed immune molecule cell lines and advanced gene editing techniques, support research and drug development in immune system functions and therapeutic advancements.
Reference
Product
Therapeutic Antibody_Benchmark Antibody Products_KYinno
Adagene
Suzhou City, China
D
11-50 Employees
2011
Key takeaway
Adagene is a clinical-stage immunotherapy company focused on redefining the discovery and design of therapeutic antibodies, which suggests a strong foundation in antibody technologies that may include bispecific antibodies. Their platform leverages precision engineering to select antibody candidates likely to achieve significant biological effects, highlighting their innovative approach in cancer treatment.
Reference
Core business
Home - Adagene
Adagene is a Nasdaq listed, global, clinical-stage immunotherapy company redefining the discovery and design of antibodies to open new horizons in the treatment of cancer.
ABclonal
Wuhan, China
D
251-500 Employees
2011
Key takeaway
ABclonal specializes in providing high-quality, customized antibodies, which aligns with the focus on improving life science research through better antibody production. Their extensive catalog and commitment to innovation in antibody development may be relevant for those interested in bispecific antibody research.
Reference
Core business
Antibody | Protein | Peptide | ELISA | Gene - ABclonal
AlpaLife
Shenzhen, China
D
11-50 Employees
2016
Key takeaway
AlpalifeBio utilizes advanced nanobody screening technology and a comprehensive molecular design platform for antibody drug discovery, highlighting their expertise in innovative approaches that could be relevant to the development of bispecific antibodies. Their commitment to enhancing drug development efficiency may also align with the needs of bispecific antibody research.
Reference
Core business
AlpalifeBio - Dedicated to Support Your Novel Nanobody/VHH and GPCR-targeted Drug Development-AlpalifeB Inc
Sanyou Bio
Huangpu District, China
D
101-250 Employees
2015
Key takeaway
Sanyou Biopharmaceuticals Co., Ltd. focuses on simplifying the R&D process for innovative biologics, including bispecific antibodies. With advanced facilities and a team of experts, they have developed a comprehensive platform for biologics discovery and optimization, emphasizing their capability in antibody specificity analysis.
Reference
Product
Antibody Specificity Analysis-Sanyou Biopharmaceuticals Co., Ltd.
Remegen
Liaoyang City, China
D
11-50 Employees
2008
Key takeaway
RemeGen has developed Telitacicept, a pioneering bispecific antibody that targets both BLyS and APRIL, marking a significant advancement in therapeutic innovations. Their product pipeline also includes Disitamab Vedotin, an original antibody-drug conjugate recognized as a breakthrough therapy.
Reference
Core business
荣昌生物制药（烟台）股份有限公司_荣昌生物
Technologies which have been searched by others and may be interesting for you:
The Bispecific Antibody industry in China presents unique opportunities and challenges for investors and researchers. One key consideration is the regulatory landscape, which is evolving as the Chinese government increasingly supports biopharmaceutical innovation. Understanding the requirements set by the National Medical Products Administration (NMPA) is crucial for navigating approval processes for bispecific antibodies. Another important aspect is the competitive landscape; numerous domestic companies are rapidly advancing in this field, contributing to a dynamic market environment. Collaborations between academia and industry can enhance research and development efforts, leading to innovative therapies. However, challenges such as intellectual property protection and market saturation must be taken into account. Environmental concerns are also relevant, especially regarding the manufacturing processes and waste management associated with biopharmaceutical production. Companies are increasingly focusing on sustainable practices to minimize their ecological footprint. Additionally, the global market relevance of bispecific antibodies cannot be overlooked, as they show promise in treating various cancers and autoimmune diseases, making them appealing not just within China but also for international markets. Overall, a thorough understanding of these factors is essential for anyone interested in the Bispecific Antibody industry in China, as they can significantly influence strategic decisions and investment outcomes.
Some interesting numbers and facts about your company results for Bispecific Antibody
| Country with most fitting companies | China |
| Amount of fitting manufacturers | 197 |
| Amount of suitable service providers | 104 |
| Average amount of employees | 101-250 |
| Oldest suiting company | 2008 |
| Youngest suiting company | 2017 |
Some interesting questions that has been asked about the results you have just received for Bispecific Antibody
What are related technologies to Bispecific Antibody?
Based on our calculations related technologies to Bispecific Antibody are Biomedical (Red), Bioinformatics (Gold), Environmental Biotechnology (Grey), Agricultural Biotechnology (Green), Food Related Biotechnology (Yellow)
Which industries are mostly working on Bispecific Antibody?
The most represented industries which are working in Bispecific Antibody are Biotechnology, Medical, Other, Pharmaceuticals, Healthcare
How does ensun find these Bispecific Antibody Companies?
ensun uses an advanced search and ranking system capable of sifting through millions of companies and hundreds of millions of products and services to identify suitable matches. This is achieved by leveraging cutting-edge technologies, including Artificial Intelligence.